ICICI Prudential Nifty Pharma Index Fund · Regular · Growth
NAV
₹19.5984
as of 14 Jul 2026
Expense Ratio
1.02%
AUM
₹97 Cr
Lumpsum returns (CAGR)
- 1Y
- +15.03%
- 3Y
- +22.18%
- 5Y
- —
- Since Inception
- +20.67%
SIP returns (XIRR)
- 1Y
- +27.44%
- 3Y
- +17.18%
- 5Y
- —
- Since Inception
- +19.41%
What history actually did — last 3 years (Jul 2023 – Jul 2026)
A ₹5,000 monthly SIP for the last 3 years (Jul 2023 – Jul 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹2,26,642 today — ₹1,80,000 invested, 16.3% XIRR.
₹1,80,000
Invested
₹2,26,642
Value today
16.3%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 3 years (Jul 2023 – Jul 2026)
Real NAV backtest
₹1,00,000 invested 3 years ago would be ₹1,81,009 today (21.9% CAGR).
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 3 years (Jul 2023 – Jul 2026) (3 Jun 2024) would be ₹1,36,109 today (1.36×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.34
Sharpe Ratio
—
Alpha
—
Beta
0.33
Sortino
15.92%
Std Dev
-11.14%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 May 2026Each sector links to the mutual funds most exposed to it.
Thinking about ICICI Prudential Nifty Pharma Index Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
Investment Objective
ICICI Prudential Nifty Pharma Index Fund · Regular · Growth is a passively managed fund that tracks a specific market index, aiming to replicate its returns with minimal tracking error. Index funds offer low-cost, diversified exposure to the market with full transparency of holdings.
About This Fund
ICICI Prudential Nifty Pharma Index Fund · Regular · Growth is a Index Fund mutual fund offered by ICICI Prudential Mutual Fund. The fund has been operational for over 3 years. It manages assets worth ₹96.8 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against Nifty Pharma TRI. The current expense ratio is 1.02%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •Cost-conscious investors who prefer passive investing with low expense ratios
- •SIP investors who can benefit from rupee cost averaging during market fluctuations